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Cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS) is a rare disorder with 31 
an unknown etiology. We present a British family with presumed autosomal dominant CANVAS 32 
with incomplete penetrance and variable expressivity. Exome sequencing identified a novel missense 33 
variant in the ELF2 gene at chr4:g.140058846 C>T, c.10G>A, p.A4T which segregated in all 34 
affected patients. By using transduced BE (2)-M17 cells, we found that the mutated ELF2 (mt-ELF2) 35 
gene increased ATXN2 and reduced ELOVL5 gene expression, the causal genes of type 2 and type 36 
38 spinocerebellar ataxias. Both, western blot and confocal microscopy confirmed an increase of 37 
ataxin-2 in BE(2)-M17 cells transduced with lentivirus expressing mt-ELF2 (CEE-mt-ELF2), which 38 
was not observed in cells transduced with lentivirus expressing wt-ELF2 (CEE-wt-ELF2). Moreover, 39 
we observed a significant decrease in the number and size of lipid droplets in the CEE-mt-ELF2-40 
transduced BE (2)-M17 cells, but not in the CEE-wt-ELF2-transduced BE (2)-M17. Furthermore, 41 
changes in the expression of ELOVL5 could be related with the reduction of lipid droplets in BE (2)-42 
M17 cells. This work supports that ELF2 gene regulates the expression of ATXN2 and ELOVL5 43 
genes, and defines new molecular links in the pathophysiology of cerebellar ataxias. 44 




The triad of cerebellar ataxia, bilateral vestibulopathy and peripheral neuropathy occurs between 9-47 
32% of patients with bilateral vestibular failure (Bronstein et al., 1991;Zingler et al., 2007). It is a 48 
rare disorder termed CANVAS (Cerebellar Ataxia, Neuropathy and bilateral Vestibular Areflexia 49 
syndrome; [MIM: 614575]). A review reported 51 patients seen over a 10-year period (Szmulewicz 50 
et al., 2015), in agreement with our own estimates of seeing 6-8 new cases per year. 51 
CANVAS is a late-onset, slowly progressive multi-system ataxia likely secondary to a 52 
neurodegenerative ganglionopathy. The combination of cerebellar ataxia and vestibular impairment 53 
produces a characteristic oculomotor sign of impaired (“broken up”) visually enhanced vestibulo-54 
ocular reflex (Migliaccio et al., 2004). Phenotypic heterogeneity in CANVAS patients is recognized 55 
(Szmulewicz et al., 2014b). Although most cases are sporadic, the finding of 6 affected siblings pairs 56 
(Szmulewicz et al., 2014a) suggests a familial recessive disorder or a dominant inheritance with 57 
incomplete penetrance, however the genes involved have not been elucidated. 58 
Case presentation 59 
We describe a non-consanguineous family with 3 CANVAS patients from England (Figure 1A). 60 
Genetic testing excluded Friedreich ataxia and SCA 1,2,3,6,7 and 38 as potential diagnoses. All 61 
patients provided written informed consent for their participation for publication and the study 62 
protocol was approved by the institutional review board. Family members in the fourth generation 63 
were examined and remained asymptomatic, however, symptom onset is typically delayed and 64 
usually over 60 years of age.   65 
Patient III:3 (proband), was a 78 year old gentleman with 20 years of progressive loss of sensation 66 
distally in upper and lower limbs and a gradual deterioration in his balance. He developed oscillopsia 67 
in 2005 and in 2014 he noticed mild slurred speech and incoordination followed by development of a 68 
prominent dry cough, difficulty with micturition and erectile dysfunction. Examination revealed 69 
dysarthria, ataxic gait and a positive Romberg test. Eye movement examination revealed downbeat 70 
nystagmus on lateral gaze. Smooth pursuit was broken horizontally and vertically. Saccades were 71 
moderately hypometric. The doll’s head-eye manoeuvre was abnormally jerky, with numerous 72 
“catch-up” saccades (abnormal visually enhanced vestibulo-ocular reflex, VVOR; (Figure 2). 73 
Horizontal and vertical head impulse tests (HIT) were positive bilaterally.  The rest of the cranial 74 
nerve examination was normal. Limb examination revealed normal tone and power throughout with 75 




no spasticity or extrapyramidal features. Reflexes were symmetrically present in the upper limbs 76 
however in the lower limbs, ankle jerks were absent and plantars were mute. There was a distal loss 77 
to light touch and pinprick sensation in all limbs, vibration sense was absent to the sternum with 78 
proprioceptive loss to ankles bilaterally. There was moderate bilateral upper and lower limb 79 
dysmetria. Romberg’s test was positive.  Normal blood tests included negative anti-neuronal, anti-80 
GAD, coeliac antibodies, anti treponemal, paraneoplastic antibodies normal B1, B12, glucose, 81 
thyroid function, Mg and vitamin E. Bithermal caloric and rotational electronystagmography 82 
confirmed bilateral absence of vestibular function. Nerve conduction study (NCS) revealed an axonal 83 
sensory neuronopathy. Sural nerve and muscle biopsy were normal. Autonomic function tests were 84 
normal. MRI brain showed cerebellar atrophy particularly involving the vermis (Figure 1B). The 85 
patient was diagnosed with CANVAS. His father (II:7) died of presumed stroke in his 60’s and his 86 
mother remained well until she died at the age of 96. Although the clinical record did not report any 87 
known neurological condition, II:8 was considered to be an obligated carrier. On further exploring 88 
the family history, it was discovered that III:6 and III:7 (maternal cousins of proband) had similar 89 
symptoms hence were also assessed. Of note, their father (II:11) had a balance disorder of unknown 90 
etiology therefore may have been affected.  91 
Patient III:6, was a 78 year old lady with a 10 year history of slowly progressive imbalance, distal 92 
numbness and dysesthesiaes. Over the last year she described dysphagia and occasional cough. Eye 93 
movement examination revealed an abnormal VVOR with head impulse test showing catch up 94 
saccades to the left. Pursuit movements were moderately broken up but in keeping with age. There 95 
was distal loss to pinprick in upper and lower limbs. Ankle reflexes were absent. She had an ataxic 96 
gait and Romberg’s was mildly positive. Bithermal caloric testing and rotational test (velocity steps 97 
and sinusoidal oscillation), showed significant bilateral reduction of vestibular function. Video-HIT 98 
showed consistent abnormal catch up saccades bilaterally. EMG/NCS confirmed a sensory 99 
neuronopathy. Autonomic function tests were normal. MRI brain revealed an incidental frontal 100 
cavernoma and mild global atrophy. This was in keeping with a diagnosis of incomplete (‘forme 101 
frustre’) CANVAS phenotype. 102 
Patient III:7, was a 74 years old lady with a 2 year history of imbalance, especially in the dark, 103 
followed by distal neuropathic symptoms and severe coughing ‘fits’. She denied any facial numbness 104 
or paresthesiae, speech or swallowing disturbance. Examination revealed a weak downbeat 105 
nystagmus in lateral gaze. Pursuit was broken in all directions and saccades were mildly hypometric. 106 
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She had an abnormal VVOR and bilateral positive HIT. Reflexes were diminished throughout and 107 
ankle jerks were absent. There was distal sensory loss to light touch and pinprick in upper and lower 108 
limbs, proprioceptive impairment to wrists and ankles. Finger-nose testing was mildly impaired in 109 
upper limbs. She had a broad based ataxic gait and Romberg’s was positive. Investigations including 110 
cerebellar screening, blood tests and genetic tests were normal. Autonomic function tests were 111 
normal. Bilateral vestibular hypofunction was confirmed on calorics and rotational test.  EMG/NCS 112 
confirmed axonal sensory neuronopathy with absent sensory nerve action potentials. MRI brain 113 
showed fissural prominence within the superior cerebellar vermis. A cervical spine MRI showed a 114 
slender lower cervical/upper thoracic cord with flattening of the posterior surface and faint signal 115 
change dorsally, compatible with dorsal root ganglionopathy. These features represent a typical 116 
CANVAS phenotype. 117 
The fourth subject (III: 2) was a 73 years old lady without any neurological symptoms and a normal 118 
neurological examination. 119 
Whole-Exome Sequencing 120 
We sequenced the exomes of 4 individuals in the family (III:3, III:6 and III:7 and III:2) (Figure 1A). 121 
Exons capture, library preparation and sequencing were performed as we previously described, in a 122 
SOLiD 5500xl platform using the reference sequence GRChr37hg19 (Martin-Sierra et al., 2016). 123 
Only variants were considered. Single nucleotide variants (SNV) with coverage >30X and minor 124 
allele frequency (MAF) <0.001 were retrieved using a combined filtering strategy (Requena et al., 125 
2017). Variants found in the non-affected sibling (III:2) (Figure 1C), were discarded and 3622 126 
variants were retained for further analyses. ANNOVAR software was used to annotate and filter 127 
SNVs. Finally, 30 heterozygous SNVs remained after filtering by exome data from the Exome 128 
Aggregation Consortium, 1000 Genomes databases and in-house controls. Twenty-seven SNVs had 129 
been previously annotated and 3 of them were novel variants. We also used LOD scores derived from 130 
WES-common SNVs to reduce the list of candidate variants, as previously described (Gazal et al., 131 
2016), and 8 candidate variants remained (Suppl. Table S1). The selected candidate variant, a 132 
missense heterozygous variant in the coding regions of ELF2 [NM_201999.2], that segregated with 133 
the phenotype was validated by Sanger sequencing. The candidate variant has been submitted to 134 
ClinVar database (http://www.ncbi. nlm.nih.gov/clinvar/).  135 




 We searched for rare variants in the ELF2 gene in exome sequencing datasets from two additional 136 
British CANVAS families, and we also performed Sanger sequencing of the ELF2 gene in these two 137 
families and a third one from Spain. So, a total of 8 additional unrelated individuals with CANVAS 138 
were sequenced, however none of them carried the variant or other rare variants in the coding regions 139 
of ELF2. 140 
The novel variant leads to a change in the exon 2 of the transcript sequence (p.A4T). The predicted 141 
effect on protein function is probably damaging, since the beginning of the coding sequence is highly 142 
conserved across species and matches with the protein N-terminal elf transcription factor domain, 143 
encoded from 4th residue to 108th residue (Suppl. Fig. S1 and S2). At protein level, the elf-2 amino 144 
acids sequence has a 67% and 57% of positive homology matches with elf-1 and ets-1, respectively. 145 
The known ETS-binding domain has 87% homology among the 3 transcription factors (TFs), and the 146 
amino acid (p.A4) is conserved in the sequence of ETS-1, ELF-1 and ELF-2 (Suppl. Fig. S3). A 147 
PAVIVE motif on N-terminal elf transcription factor domain, a relevant recognition motif in elf 148 
family, is conserved between elf-1 and elf-2 amino acids sequences. 149 
BE(2)-M17 cell culture  150 
Human neuroblastoma BE(2)-M17 cell line (ATCC® CRL-2267™) was cultured and RT–PCR was 151 
used to confirm that the ELF2, ATXN2 and ELOV5L genes are constitutively expressed in BE(2)-152 
M17 neuroblastoma cell line (Suppl Fig. S4 A and C). 153 
Lentiviral vector constructs production and neuroblastoma transduction. 154 
The cDNA encoding for human ELF2 gene and the ELF2 gene with the variant described was cloned 155 
in the bicistronic lentiviral vector (LV) pHRSINcppt_CMVeGFP_ELF1α-TetR (also named CEET, 156 
available in our laboratory) using standard molecular biology techniques (PacI/MreI (Sse232I)) to 157 
obtain the lentiviral plasmids CEE-wt-ELF2 and CEE-mt-ELF2 respectively. Both LV expressed 158 
eGFP in addition to the wtELF2 or the mtELF2. LVs production was performed as previously 159 
described (Frecha et al., 2008). All the LVs used were titrated based on the percentage of eGFP 160 
expressing cells as previously described (Benabdellah et al., 2014).  161 
The transduction efficiency was 95%. The number of LV integrated per cell was estimated by qRT-162 
PCR as previously described (Cobo et al., 2013). Transduction was measured at 3, 7, 10 and 25 163 
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days). No significant differences were found between both transduced cell lines. Moreover, the 164 
transduction remained stable over time after day 3 (Suppl Fig. S4B). 165 
Cell viability and proliferation assays 166 
Cell viability and proliferation assays were performed in BE(2)-M17 cells to investigate the effect of 167 
the ELF2 variant. For both cell viability and proliferation assays, there was no difference between the 168 
cells. (Suppl. Fig. S5). These results suggest that overexpression of wt-ELF2 or mt-ELF2 gene did 169 
not have any influence on the proliferation or survival of BE(2)-M17 cells and overexpression of 170 
ATXN2 did not modify the morphology.  171 
Functional assays: qRT-PCR, Western blot, immunocytochemistry and confocal microscopy 172 
We also investigated the effect of mutant ELF2 on ATNX2 and ELOVL5 expression levels, since 173 
these genes are a direct target of ELF2, according to Curated Transcription Factor Targets Dataset 174 
(TRANSFAC), and both have been associated with SCA2 and SCA38 (Scoles et al., 2012;Di 175 
Gregorio et al., 2014;Hoxha et al., 2017).  176 
We confirmed that ELF2, ATXN2 and ELOVL5 genes were constitutively expressed in BE(2)-M17 177 
cells by RT-PCR.  We then evaluated ELF2, ATXN2 and ELOVL5 gene expression in CEE-wt-ELF2- 178 
and CEE-mt-ELF2- transduced BE(2)-M17 cells by qPCR and Western blot and found a significant 179 
increase in both ELF2 (p=0.03) and ATNX2 (p=0.002) expression at mRNA levels in the cells 180 
transduced with the CEE-mt-ELF2, but not in cells transduced with the CEE-wt-ELF2 (Figure 3A). 181 
In contrast, ELOVL5 was significantly decreased (p=0.003) in cells transduced with the CEE-mt-182 
ELF2, but not in cells transduced with the CEE-wt-ELF2 (Figure 3D). The ATXN2 increase was 183 
confirmed at protein levels in the CEE-mt-ELF2- transduced BE(2)-M17 cells, when they were 184 
compared to the wild type cell line (p=0.019, Figure 3A and B).  185 
Confocal microscopy imaging illustrated an overexpressed cytoplasmic distribution of ataxin-2 in 186 
CEE-mt-ELF2-transduced BE(2)M17 cells. We quantified the fluorescence intensity levels (Fig 3D). 187 
CEE-mt-ELF2 cell line was the most intensely labelled, followed by those cells that were not 188 
transduced and finally wt-ELF2 cells. Significant differences were found among non-transduced cells 189 
compared to mt-ELF2 (p=0.03) and between wt-ELF2 as compared to mt-ELF2 (p=0.003, Figure 190 
3C). In addition, the immunocytochemistry showed that the transduction and mutation did not change 191 
elf2 location. 192 




On comparing non-transduced BE(2)M17 cells with CEE-mt-ELF2 BE(2)M17-transduced cells, 193 
significant differences in the number of lipid droplets were observed with reduced lipid droplets 194 
present in the mutant cell line (p=0.02, Figure 4A and C). In addition, we observed that lipid droplets 195 
were smaller in CEE-mt-ELF2 transduced BE(2)M17 cells (0.68±0.05) when compared with CEE-196 
wt-ELF2 BE(2)M17 transduced cells (1.53±0.14, p=1.54x10-8) and non-transduced BE(2)M17 cells 197 
(1.83±0.03, p=1.55x10-48, Figure 4B). 198 
BACKGROUND 199 
The ETS gene family is a group of TFs divided in 12 subfamilies. The ETS subfamily includes ETS1 200 
and ETS2; the ELF subfamily includes ELF1, ELF2 and ELF4 (MEF) genes and the ELG subfamily 201 
consist of GABPα. All ETS TFs are defined by a highly conserved DNA binding domain, the ETS 202 
domain with a core GGA(A/T) DNA sequence (Sharrocks, 2001). Previous electromobility shift 203 
assays (EMSA) have demonstrated that ETS1, ELF2 and GABPα interact with the ETS domain 204 
within the 5´-UTR in the ATXN2 gene in HEK293 and SH-SY5Y nuclear lysates. HEK293 cells 205 
overexpressing ETS1 showed an increase in the expression of ATXN2 gene (Scoles et al., 2012). 206 
These findings suggested that the ETS domain in ATXN2 may be regulated by other TFs of the ETS 207 
gene family such as ELF-2. In the present study, we identified a novel missense variant in the ELF2 208 
gene (E74-like factor 2; NERF), which segregates the complete phenotype and we present functional 209 
data showing the effect of mutated ELF2 (mt-ELF2) gene on ATXN2 and ELOVL5 two genes 210 
previously associated with spinocerebellar ataxia 2 and 38 (SCA2 and SCA38). No similar phenotype 211 
has been linked to ELF2 mutations at the time of submission (see Concluding Remarks).  212 
 213 
DISCUSSION 214 
CANVAS is a rare syndrome, with less than 500 cases described worldwide  (Szmulewicz  et al. 215 
2015), and familial cases have been described rarely (Szmulewicz et al., 2014a). We report a family 216 
with 3 CANVAS patients segregating a novel variant in ELF2 gene. Several lines of evidence 217 
support a pathogenic role for the ELF2 variant in this family. Firstly, multiple bioinformatics tools 218 
ranked this variant at the top of the candidate list; secondly, this novel variant was not found in the 219 
gnomAD and, perhaps more conclusively, the mt-ELF2 in a neuroblastoma cell line was able to 220 
modify the gene expression of two genes associated with ataxia in two ways. Firstly, by upregulating 221 
the expression and translation of ATXN2 (the gene involved in SCA2) and secondly, by decreasing 222 
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the expression and translation of ELOVL5, (associated with SCA 38). Sequencing data were re-223 
evaluated in our familial dataset in both genes, but no abnormal CAG repeat expansion in ATXN2 or 224 
pathogenic variants in ELOVL5 gene such as c.214C>G or c.689G>T l were found in the patients. 225 
ELF2 is a TF associated with RUNX1 and both interact in the regulation of gene expression (Wang 226 
et al., 1993). We have observed that ELF2 acts as a repressor of ATXN2 gene expression in 227 
neuroblastoma cells and that mt-ELF2 will not be likely to regulate its expression. Although our 228 
mutation is not within the ETS-binding domain, it is not possible to exclude the interaction of ELF2 229 
and other TFs, such as RUNX1.   230 
ELOVL5 is a target gene for ELF2 according to the TRANSFAC (Wingender et al., 2000;Wingender, 231 
2008) and this gene is considered the causal gene of SCA 38 (Di Gregorio et al., 2014). Our results 232 
also confirm that mt-ELF2 also modifies the expression of ELOVL5. This gene is involved in the 233 
long-chain fatty acids elongation cycle, and it is highly expressed in Purkinje cells.  Furthermore, the 234 
ELOVL5-/- mice develop ataxia and motor impairment during the balance beam test (Hoxha et al., 235 
2017). Several neurological diseases, particularly hereditary spastic paraplegias (Dick et al., 236 
2010;Tesson et al., 2012;Boukhris et al., 2013;Martin et al., 2013) display alterations of  lipid 237 
metabolism. Increases in lipid droplets play a crucial role in the nervous system and have been 238 
associated with in vitro models of neurodegenerative disorders such as Huntington’s and Parkinson’s 239 
diseases (Martinez-Vicente et al., 2010;Thiam et al., 2013;Welte, 2015), emphasising the importance 240 
of lipid homeostasis in brain membranes. 241 
Although the expression of ELF2 gene in the human cerebellum is low according to the Allen Brain 242 
Atlas (http://www.brain-map.org/) (Hawrylycz et al., 2012), and the same variant was not observed 243 
in other CANVAS patients, this may be attributed to the genetic heterogeneity commonly found in 244 
hereditary ataxias. 245 
Furthermore, we have found strong evidence that the position chr4: g.140058846 C>T in the ELF2 246 
gene is highly conserved in an evolutionary sense, therefore the variant is likely pathogenic and  247 
possibly interferes with protein function. Functional assays indicate a regulatory role of the ELF2 248 
variant in vitro for two SCA genes, since we have shown that the expression of mt-ELF2, but not wt-249 
ELF2, increases ATXN2 gene expression and ataxin-2 translation and decreases ELOVL5 gene 250 
expression in BE(2)-M17 cells.  251 
CONCLUDING REMARKS 252 




We describe a novel variant in ELF2 gene in this family with CANVAS syndrome and demonstrate 253 
its functional effects in ATXN2 and ELOV5 genes in BE(2)-M17 transduced cells. The interaction 254 
between ELF2, ATXN2 and ELOVL5 genes found suggests that the regulation of expression in these 255 
genes could potentially be a shared mechanism in hereditary ataxias.  256 
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15 
Figure legends 393 
FIGURE 1. Genetic diagnosis of familial CANVAS: (A) Pedigree of an autosomal dominant 394 
CANVAS family with three affected cases with the age of onset. (B) Sagittal MRI showing 395 
cerebellar atrophy in patient III:3. (C) Chromatogram of reverse chain of the variant chr4: 396 
g.140058846 G>A from an affected individual (III.3) is compared to the sequence from a familial 397 
control (III.2).  398 
 399 
FIGURE 2. Head and eye horizontal movements in the CANVAS proband.  The patient fixates a 400 
visual target on the wall while the examiner manually oscillates his head from behind in a quasi-401 
sinusoidal fashion (visually-assisted vestibulo-ocular reflex or VVOR). The compensatory eye 402 
movement elicited is severely broken-up or cog-wheeled due to the presence of multiple eye saccades 403 
(best seen as ‘spikes’ in the eye velocity trace). Upwards deflections correspond to rightwards head 404 
or eye movements. 405 
 406 
FIGURE 3.ATXN2 expression in BE(2)M17, wt-ELF2 and mt-ELF2 transduced cells. (A) 407 
ATXN2 qPCR and ataxin-2 Western blot show statistical differences between wt-ELF2 and mt-ELF2 408 
transduced cells, both in qPCR and Western blot. (B) Representative western blot of BE(2)M17 409 
exhibiting an increased content of ATXN2 in mt-ELF2 transduced cells. ATXN2 (#611378, 1:1000), 410 
Elf2 (#HPA006057-100UL, 1:1000) GAPDH (#AB2302, 1:3000 and secondary antibodies 411 
#HAF007, 1:6000, #HAF008, 1:3000, #A9046-1ML, 1:10000. (C) CTCF emitted by BE(2)M17 cells 412 
labelled with anti-ataxin-2 antibody in non-transduced,wt-ELF2 transduced and mt-ELF2 cells. (D) 413 
Representative immunocytochemistry image of ataxin-2 in non-transduced BE(2)M17, wt-ELF2 and 414 
mt-ELF2 transduced cells showing an increased staining in mt-ELF2 cell-line. * p<0.02, ** p<0.002. 415 
Primary antibodies anti-ataxin-2 (1:250) and anti-ELF2 (1:500) and visualized with Alexa-555-416 
conjugated goat anti-mouse #A-21422, 1:500 and Alexa-633-conjugated goat anti-rabbit #A-21071, 417 
1:500, respectively. (E) ELOVL5 qPCR show statistical differences between wt-ELF2 and mt-ELF2 418 
transduced cells. * p<0.003 419 
 420 




FIGURE 4. Changes in Lipid droplets in transduced BE(2)M17 cell-lines. (A)Number of lipid 421 
droplets particles per cell in each cell-line (*p=0.02). (B) Mean of particles size in every cell-line. 422 
*BE(2)M17 non-transduced cells vs wt-ELF2 cells (p=0.03); **wt-ELF2 vs mt-ELF2 transduced 423 
cells (p=1.54x10-8); ***BE(2)M17 vs mt-ELF2 (p=1.55x10-48). (C) Representative 424 
immunocytochemistry image of Lipid droplets stained with Nile Red in non-transduced BE(2)M17, 425 
wt-ELF2 and mt-ELF2 transduced cells showing a decrease number and size of the droplets in mt-426 
ELF2 cell-line. For lipid droplets experiments, cells were stained with Nile red to measure the 427 
number and size of lipid droplets. After Nile red staining, cells were fixed and staining with anti-428 
ELF2 (1:500) and visualized with Alexa-633-conjugated goat anti-rabbit (1:500).  429 
